Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813248 | 0.79 | POLB (0.38) | KMT2ALMNAALDH1A1 | |
| SCHEMBL11451436 | 0.77 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL1810200 | 0.76 | NPSR1 (0.33) | MEN1KMT2ALMNANPSR1CYP3A4 | |
| SCHEMBL11391284 | 0.76 | CYP4F2 (0.33) | — | |
| SCHEMBL5697628 | 0.76 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL18329678 | 0.74 | PKM (0.43) | KMT2A | |
| SCHEMBL11642460 | 0.73 | MAPT (0.31) | MEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL11490346 | 0.72 | MEN1 (0.34) | MEN1KMT2ALMNANPSR1 | |
| SCHEMBL289296 | 0.71 | — | — | |
| SCHEMBL390361 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746113-B2 | Labelled cannabinergic ligands and related analogs | MAKRIYANNIS ALEXANDROS (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | MAKRIYANNIS ALEXANDROS (US) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746113-B2 | Labelled cannabinergic ligands and related analogs | CNR1, CNR2, CHRND | MEN1 3854/4885KMT2A 4637/4885LMNA 2297/4885 |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | CNR1, CNR2, CHRND | MEN1 4141/4885KMT2A 4575/4885LMNA 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.